Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor Virus-Specific T-cells for CMV or AdV Reactivation After Transplant
NCT03665675Phase 1Recruiting
- Start
- Nov 2020
- Primary completion
- Mar 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of cytomegalovirus-specific T cells and allogeneic adenovirus-specific cytotoxic T lymphocytes in cytomegalovirus infection (CMV) and adenovirus infection (2 arms). Primary endpoints: Incidence of adverse events at 30 days and Feasibility of identifying donor and meeting T cell doses at 1 year. Started Nov 2020; status: recruiting.
02
Drugs
cytomegalovirus-specific T cellsallogeneic adenovirus-specific cytotoxic T lymphocytes
03
Conditions
cytomegalovirus infection (CMV)adenovirus infection
Beyond the preview
Go deeper on NCT03665675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665675.